Anglo-Swedish pharmaceuticals group AstraZeneca has sold Quorn, a leading brand of vegetarian meat-substitute products, to Montagu Private Equity for £70m (US$115.1m).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AstraZeneca put Marlow Foods, which makes and distributes Quorn, up for sale a year ago, when the business was estimated to be worth around £100m, reported the Financial Times.
Quorn, which is based on mycoprotein, a plant related to edible fungi such as mushrooms, is sold across Europe and was introduced onto the US market last year. US sales are currently at more than US$5m at retail value, although nearly three-quarters of sales of Quorn products are made in the UK.
